We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Length-affecting mutations (insertions or deletions) within exon 9 of the Calreticulin (CALR) gene have been described in approximately 70% of essential thrombocythemia (ET) and approximately 60-80% of primary myelofibrosis (PMF) patients without JAK2 or MPL mutations. CALR exon 9 insertion/deletion mutations have not been identified in polycythemia vera (PV) patients.
Organ: Blood/Bone Marrow
CPT Code(s): 81219 (reference only; CPTs may vary)
Turnaround Time: Within 4-8 business days of receipt
Formalin-fixed, paraffin-embedded (FFPE) tissue block, 10 FFPE tissue slides, or peripheral blood or bone marrow in EDTA or heparin.